FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/18/2025
Back to search
Official data from USPTO
RIBORENOSTAR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
RIBORENOSTAR
ST13
US500000079387958Class
5, 42
Filing
79387958
Registration
7726224
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
04/03/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
11/10/2023
Registration date
03/18/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/18/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
CN
Examiner
MASON, JARED MICHAEL
Law office
N10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Suzhou Ribo Life Science Co., Ltd.
Representatives
Zhi Dong HSML, P.C.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for humans for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; drugs for medical purposespharmaceutical preparations for the treatment and diagnosis of cardiovascular diseasesmetabolic diseasesliver diseasesgenetic disorders and rare ocularrespiratorygastrointestinalcerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceuticals for the treatment of cancer; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceuticals for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic food and beverages adapted for medical use; depuratives for the body; medicines for veterinary purposesveterinary preparations for the treatment and diagnosis of gastrointestinal diseasescardiovascular diseasesmetabolic diseasesliver diseases; pesticides; dressingsmedical; composite materials for dental purposes; diapers for pets
Class 42
Technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development services; research in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/26/2025
FIMP
FINAL DISPOSITION PROCESSED
09/26/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/11/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/24/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/24/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/18/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
03/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/28/2025
PUBO
PUBLISHED FOR OPPOSITION
01/28/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/22/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
01/02/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/02/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
01/02/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/30/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/30/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/30/2024
RFNT
REFUSAL PROCESSED BY IB
07/28/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/11/2024
RFRR
REFUSAL PROCESSED BY MPU
07/11/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/21/2024
CNRT
NON-FINAL ACTION WRITTEN
06/20/2024
DOCK
ASSIGNED TO EXAMINER
06/18/2024
MAFR
APPLICATION FILING RECEIPT MAILED
01/30/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/26/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/25/2024
Continuous trademark protection
Get notified about every new filing that threatens RIBORENOSTAR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.